ZURICH, July 29 (Reuters) - A late-stage clinical trial of Roche's ROG.S Actemra/RoActemra drug to treat patients hospitalised with severe COVID-19-related pneumonia failed, the drugmaker said on Wednesday.
The "COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality," Roche said.
(Reporting by John Revill; Editing by Michael Shields)
((John.Revill@thomsonreuters.com; +41 58306 7022; Reuters Messaging: email@example.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.